Thymosin alpha-1
Not studied for general immune boosting in healthy people.
A peptide that nudges . Approved in more than 35 countries for hepatitis and as an immune booster in illness, but never in the US. Its largest modern trial was negative. Also called Thymalfasin, Zadaxin and Tα1.
What the evidence shows
Side effects and risks
Who should avoid it: Transplant recipients and people on immune-suppressing treatment, unless a specialist advises it.
How it works
- Where it acts
- Toll-like receptors on immune cells.
- What it changes
- It helps T cells mature and boosts immune signalling.
- What people notice
- Used as an add-on for hepatitis B and in cancer care in some countries. Few side effects, and inconsistent benefit.
How it has been given in studies
Hepatitis trials used 1.6 mg injected under the skin twice a week. Other studies ranged from 0.8 mg to 6.4 mg.
Getting it in the United States
The legal route for Thymosin alpha-1
Not FDA-approved and not eligible for pharmacy compounding. Vials sold for research use only are unapproved drugs when marketed for people.
Routes people use for any peptide in the United States
Telehealth prescribing
Online clinics prescribe after a questionnaire, sometimes with no live doctor visit, and mail the drug. FDA moved in February 2026 to restrict mass-marketed compounded copies and claims that they are generic equivalents.
Risk: Thin medical screening. Compounded versions are not reviewed by FDA for quality.
Covers: Approved GLP-1 drugs, compounded semaglutide and tirzepatide
Source: GZERO Media, Apr 2026
Clinical trial enrolment
The only lawful way to get an unapproved peptide drug with medical monitoring. ClinicalTrials.gov lists eligibility, sites and phone numbers. Researchers note recruitment is hard when people can buy the drug on the gray market instead of risking placebo.
Risk: Possible placebo assignment, strict eligibility and travel to a study site.
Covers: Investigational peptide drugs still in development
Source: NIH, finding a clinical trial
Compounding pharmacies
FDA lists thymosin alpha-1 among substances that sat in Category 2 until their nominators withdrew them. The agency still says safety data are inadequate. Patients relying on compounded supply face unclear quality and legal footing.
Advisory committee nomination
In 2024-12 FDA's compounding advisory committee reviewed it for uses including hepatitis B and C, HIV, COVID-19, three cancers, sepsis, COPD and ME/CFS. No US-approved product exists, so access depends on that process.
Routes people use for any peptide in the United States
Compounding pharmacy with prescription
A clinician prescribes and a pharmacy compounds. Twelve peptides left the FDA do-not-compound category in April 2026 and a panel backed six in July, but they are not yet formally eligible. Pharmaceutical-grade ingredient is scarce.
Risk: Legal status is unsettled until FDA rulemaking ends. Pharmacies may use research-grade ingredient.
Covers: BPC-157, TB-500, KPV, MOTS-c, Semax, Epitalon and similar
Source: Frier Levitt, Apr 2026
Med spas and weight-loss clinics
Very common. Secret shoppers called 75 clinics and med spas in two states after shortages ended. 92 percent offered compounded semaglutide and 87 percent tirzepatide, often mixed with B vitamins to look custom.
Risk: Four of 23 suppliers lacked sterile compounding licenses and four had disciplinary records.
Covers: Compounded semaglutide and tirzepatide
Source: American Med Spa Association on JAMA Health Forum study, Jul 2026
Concierge and longevity doctors
Cash-pay physicians build peptide plans for wealthy clients. Reporting from San Francisco says some source from overseas channels, domestic research-use-only sellers or the few compounding pharmacies that will supply clinicians.
Risk: A doctor's involvement does not guarantee a pharmaceutical-grade product.
Covers: BPC-157, thymosin alpha-1, Selank, Semax, CJC-1295, ipamorelin, retatrutide
Source: San Francisco Standard, Sep 2025
Cross-border purchase or import
FDA says importing drugs for personal use is illegal in most cases but it may not object to small personal quantities in limited situations. Reporting also describes people travelling to Mexico for injections.
Risk: Packages can be seized. Product origin and cold-chain handling are hard to check.
Covers: Approved prescription peptides sold abroad
Source: FDA, personal importation
Routes people use for any peptide in the United States
Research-chemical websites
Sites sell vials marked for research or not for human consumption, with no prescription. FDA says some ship direct to consumers with dosing directions, and it has sent warning letters. Retatrutide exists only through this route or trials.
Risk: Unknown identity, strength and sterility. No pharmacist or prescriber involved.
Covers: Retatrutide, semaglutide, tirzepatide, BPC-157 and most unapproved peptides
Source: FDA, unapproved GLP-1 drugs page
Direct orders from Chinese factories
Buyers message factory sales agents and pay by crypto or payment app. A minimum order of about ten vials pushes people to buy in bulk and share. A blockchain analysis found US buyers were the largest source of funds.
Risk: Many of the same vendors list fentanyl precursors. Lab reports sent by sellers cannot be verified.
Covers: GLP-1 copies, melanotan II, BPC-157, TB-500, GHK-Cu, epitalon
Source: TRM Labs, Oct 2026
Chat groups and social sellers
Dealers are found through Telegram, WhatsApp, Discord and influencer discount codes. In a May 2026 survey of 1,000 US users, 14.5 percent bought this way and three quarters asked an AI chatbot for dosing.
Risk: 45 percent of social media buyers in that survey reported an emergency or urgent care visit for a reaction.
Covers: Retatrutide and other research-use-only peptides
Source: The Ethos, May 2026
This describes what people do. It is not advice. The decision is yours.
What users report
Recurring themes in public forum posts, unverified and with no comparison group.
Reported benefits
- Fewer colds
- Popular in chronic-illness communities
Reported problems
- Tiredness or flu-like feeling
- Injection-site soreness
- Impossible to tell if it did anything
What experts and influencers say
Recorded views, not a survey or scientific consensus. Cautions may concern misuse or unapproved products. Statements are paraphrased; check each source for context.
Supportive expert view
No sourced expert view in this category yet. See the full list for other perspectives.
Cautionary expert view
Calls the craze unfounded. He found no randomized human trial showing the advertised benefits for any of the unapproved peptides he reviewed, and warns about stacking several at once. He points to animal work in which TB-500 sped up dormant tumor growth and to a theoretical cancer concern with growth-hormone peptides and BPC-157. He treats the GLP-1 drugs as the well-studied exception.
Source: Eric Topol, "The Peptide Craze", Jul 2025, Associated Press, Nov 2025
Eric TopolWebsiteWarns against
See all views 5
Their phase 3 trial in 1,106 adults with sepsis found no clear evidence that thymosin alpha-1 lowers 28-day death. They reported a good safety profile.
Source: BMJ, 2025-01
Calls the craze unfounded. He found no randomized human trial showing the advertised benefits for any of the unapproved peptides he reviewed, and warns about stacking several at once. He points to animal work in which TB-500 sped up dormant tumor growth and to a theoretical cancer concern with growth-hormone peptides and BPC-157. He treats the GLP-1 drugs as the well-studied exception.
Source: Eric Topol, "The Peptide Craze", Jul 2025, Associated Press, Nov 2025
Eric TopolWebsiteWarns against
Pooled 11 Chinese trials with 1,927 patients. Overall deaths were lower, but higher-quality and multicentre trials showed no significant benefit and a test suggested publication bias. They call the evidence inconclusive.
Source: Frontiers in Cellular and Infection Microbiology, 2025-09
Bin Gu and colleagues, Sun Yat-sen UniversitySourceMixed view
Says safety information is too thin for it to understand the extent of any safety problems with compounded thymosin alpha-1. Also flags possible immune reactions and peptide impurities.
US Food and Drug AdministrationSourceWarns against
Pooled 8 studies and found lower death rates in moderate to critical COVID-19, with no change in ventilation or hospital stay. Results varied widely between studies and they asked for randomised trials.
Source: Inflammopharmacology, 2023
A. Y. Soeroto and colleaguesSourceMixed view
More contextCase reports, watch and read, emerging uses and chemistry
Case reports
From journals, regulators and studies of users. One case proves little.
Mixed resulttrial result in rare group - 1106 people - 2025
In the TESTS sepsis trial, patients with diabetes and those aged 60 or over trended toward fewer deaths on the drug. Patients under 60 trended toward more. The subgroup signals missed the trial's strict threshold and are exploratory.
Source: BMJ, 2025-01
Watch and read
Explainers, reporting and podcasts worth your time. Summaries are ours. No sellers.
Certain Bulk Drug Substances for Use in Compounding that May Present Significant Safety Risks
FDA
FDA lists thymosin alpha-1 among compounding substances nominated then withdrawn, citing immunogenicity and characterization concerns and inadequate safety information.
Regulator warning on compounded thymosin alpha-1
When options run out
Uses people turn to when standard treatment has failed.
Sepsis in patients with cancer
- Who
- Intensive care teams treating septic patients whose immune systems are already weakened by cancer.
- Evidence
- Patient-level analysis of two large trials found no overall survival gain. A possible benefit in cancer patients was rated moderate credibility. Diabetes and heart disease signals were rated low.
- Route
- Randomised trials in Chinese hospitals
Source: Frontiers in Cellular and Infection Microbiology, 2025-09
Long COVID immune rebalancing
- Who
- People with lasting post-viral symptoms and no approved treatment look to it to restore T-cell function.
- Evidence
- Only small observational studies in post-viral syndromes. No large placebo-controlled trials. Not approved for this use and no clinical guideline recommends it.
Source: Science Insights, 2025-11
Post-treatment Lyme disease syndrome
- Who
- Patients with fatigue, brain fog and nerve symptoms after Lyme treatment. A peptide podcast says some doctors use it off-label for them.
- Evidence
- Doctor reports relayed by a podcast supported by partner brands. No trial results are given. FDA also listed ME/CFS among uses nominated for compounding.
Legal last-resort routes
Expanded access (compassionate use)
For a serious or life-threatening condition with no comparable alternative and no trial you can join. Your physician asks the company for the drug, then files with FDA and an ethics board. The company can refuse. Costs are often not insured.
Right to Try
For a life-threatening condition after approved options are exhausted and no trial is open to you. The drug must have finished Phase 1 and be in active development. Your doctor asks the manufacturer directly. FDA does not review requests.
Source: FDA, Right to Try
Trial finders
Search ClinicalTrials.gov by condition or drug name, check eligibility and call the listed site. ResearchMatch is a free NIH-funded registry that lets researchers find you. Discuss risks with your own clinician before enrolling.
Source: NIH, finding a clinical trial
Personal import for serious conditions
FDA may not object when a US citizen imports up to about three months of a drug for a serious condition with no effective US treatment, with written personal-use confirmation and a US doctor's details. It is discretion, not a right.
Source: FDA, personal importation
Patient-specific compounding
When the approved product cannot meet a specific need of an identified patient, a prescriber can order a compounded version from a licensed pharmacy. Lower price alone does not qualify. Ingredients must be pharmaceutical grade.
Amino-acid sequence
Questions people ask
Does thymosin alpha-1 boost the immune system?
It helps T cells mature and boosts immune signalling, but general immune boosting in healthy people has not been studied. Its largest modern trial, in 1,106 patients with sepsis, found no difference in deaths at 28 days.
Is thymosin alpha-1 FDA approved?
No. It is approved in more than 35 countries for hepatitis and as an immune booster in illness, but never in the US, and its US compounding nomination was withdrawn.
Does thymosin alpha-1 help with COVID-19?
Observational studies conflict, and an apparent benefit vanished after adjusting for patient differences. There is no large randomized trial.
Who should avoid thymosin alpha-1?
Transplant recipients and people on immune-suppressing treatment, unless a specialist advises it. It stimulates the immune system, and FDA calls the safety information for compounded versions inadequate.
Your notebook
Taking it? A ten-second daily check-in keeps a record of how you feel, to talk through with your clinician.
Sources
- TESTS trial 2025: thymosin alpha-1 for sepsis
- Ciancio et al. 2012: thymosin alpha-1 added to hepatitis C treatment
- Tao et al. 2023: review of thymosin alpha-1
- Partnership for Safe Medicines: peptide import records (9 Jun 2026)
- FDA: bulk substances that may present significant safety risks
Structure: PubChem